michigan glp-1 stomach paralysis attorney gastrointestinal obstruction law office in A 76-year-old woman's wrongful death claim glp-1 stomach paralysis law office

The drug is mainly used to treat obesity and type 2 diabetes, and has attracted much attention for its excellent weight loss and blood sugar control effects

Researchers have reported that GLP-1 drugs that contain the active ingredient tirzepatide may be more effective for weight loss than GLP-1 medications that contain the active ingredient semaglutide

This suggests the eventual prescribing approach may involve reaching a target weight and then adjusting the dose downward to maintain it, rather than stopping treatment entirely

Cardiometabolic risk minimization: Due to its impact on weight and glucose metabolism, Retatrutide may potentially reduce long-term cardiovascular risk factors (such as high blood pressure), though definitive outcomes are still under investigation

Yes, oral semaglutide and injectable semaglutide generally have the same side effects because they share a similar active ingredient

Retatrutide, developed by Eli Lilly under the code LY3437943, is a synthetic peptide that simultaneously activates three incretin and metabolic receptors: GLP-1, GIP, and glucagon